Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE6D | O43924 | 1/20 | 0.38 |
| ▸ | PDE6A | P16499 | 1/20 | 0.38 |
| ▸ | PDE6G | P18545 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE6B | P35913 | 1/20 | 0.38 |
| ▸ | PDE6C | P51160 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.38 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8360079 | 0.93 | PDE5A (0.51) | PDE5A | |
| SCHEMBL8360697 | 0.92 | PDE5A (0.51) | PDE5A | |
| SCHEMBL16299631 | 0.92 | PDE5A (0.46) | PDE5APDE4BPDE7A | |
| SCHEMBL6669930 | 0.92 | PDE5A (0.48) | PDE5APDE4BPDE7A | |
| SCHEMBL10201510 | 0.92 | PDE5A (0.39) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL8212990 | 0.90 | PDE5A (0.51) | PDE5A | |
| SCHEMBL10201548 | 0.88 | PDE4B (0.40) | PDE5APDE4BPDE7A | |
| SCHEMBL10201520 | 0.87 | DPP4 (0.40) | PDE5APDE4BPDE7A | |
| SCHEMBL6670564 | 0.86 | PDE4B (0.35) | PDE5APDE4BPDE6DPDE6APDE6G | |
| SCHEMBL7886157 | 0.85 | PDE5A (0.51) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9006258-B2 | Method of treating female sexual dysfunction with a PDE1 inhibitor | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20100323997-A1 | NOVEL USES | INTRACELLULAR THERAPIES, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010132127-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010098839-A1 | PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2008070095-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008063505-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1421084-B1 | POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1790652-A1 | Polycyclic guanine phosphodiesterase V inhibitors | Schering Corporation (US) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885PDE4B 8/4885PDE6D 117/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE4B 24/4885PDE6D 126/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE5A 2/4885PDE4B 9/4885PDE6D 76/4885 |
| US-20110312978-A1 | PDE1 INHIBITORS FOR OPHTHALMIC DISORDERS | PDE12, PDE5A, PDE3A | PDE5A 2/4885PDE4B 12/4885PDE6D 18/4885 |
| US-20100323997-A1 | NOVEL USES | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE4B 7/4885PDE6D 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.